Alzheimer's Disease Treatment Medications: Identified Options and Financial Aid
Alzheimer's disease (AD) is a progressive condition that begins with memory issues and can lead to the loss of a person's ability to respond to their environment and communicate with others. While there is currently no cure for AD, medical management can help improve a person's quality of life and may reduce certain symptoms.
Traditionally, cholinesterase inhibitors (such as donepezil, rivastigmine) and NMDA receptor antagonist memantine have been used to manage cognitive symptoms in mild to moderate AD, including some late-stage patients. These drugs work by enhancing neurotransmitter function to improve cognition and behavior but do not alter disease progression.
In recent years, new treatments and disease-modifying therapies have emerged, targeting the underlying pathology, especially amyloid beta plaques. One such treatment is lecanemab, a humanized monoclonal antibody approved in 2023. Lecanemab is suitable for those with mild cognitive impairment or mild dementia and has demonstrated sustained efficacy over four years, slowing cognitive decline and functional deterioration primarily in early-stage patients.
Another anti-amyloid antibody, donanemab, has shown in a Phase 3 extension study that early intervention slows memory and thinking decline over three years and results in substantial amyloid clearance. Like lecanemab, it aims to modify the disease course by targeting amyloid plaques.
Medicare typically helps cover prescription medications to treat AD, but as of now, it does not cover aducanumab or lecanemab unless the person has enrolment in an approved clinical trial. Aducanumab, the first disease-modifying drug with approval for treating AD, helps reduce the buildup of atypical proteins called amyloid deposits in the brain.
For late-stage Alzheimer's, disease-modifying therapies like lecanemab and donanemab were primarily tested in early stages, and data for symptomatic or late-stage patients remain limited. Treatment in late-stage primarily involves managing symptoms, behavioral issues, and complications, often using cholinesterase inhibitors and memantine.
Common side effects of cholinesterase inhibitors include nausea, vomiting, fatigue, diarrhea, and muscle cramps. Memantine, on the other hand, works by regulating a brain chemical called glutamate and may decrease symptoms and prolong a person's ability to maintain daily functions.
Private insurance, retiree health coverage, group employee plans, employee benefits, and Veteran benefits may help cover the cost of AD medications. A person with dementia may also qualify for various public programs, including Medicaid, for income support and social security income disability.
The progression in AD treatment focuses on early intervention with amyloid-targeting antibodies to slow disease progression, symptomatic management with conventional drugs for cognition and behavior, and ongoing research into repurposing other drugs and novel mechanisms. These therapies provide modest slowing of the disease rather than a cure, emphasizing the need for early diagnosis and treatment initiation.
- The treatment of Alzheimer's disease (AD) includes disease-modifying therapies like lecanemab, which is a humanized monoclonal antibody, and donanemab, an anti-amyloid antibody, designed to target the underlying pathology, especially amyloid beta plaques.
- Medicare typically covers prescription medications for Alzheimer's disease, but as of now, it does not cover lecanemab or donanemab unless the person is enrolled in an approved clinical trial.
- For late-stage Alzheimer's, traditional treatments like cholinesterase inhibitors and memantine are primarily used to manage symptoms, behavioral issues, and complications.
- In health-and-wellness and medical-conditions discussions, it's important to consider various therapies and treatments for neurological disorders like AD, including ongoing research into repurposing other drugs and novel mechanisms, as the progression in AD treatment focuses on early intervention.
